For patients with locally advanced, unresectable non-small cell lung cancer (NSCLC), standard use of the more accurate ...
In April, miners and mining labor leaders met with U.S. Department of Labor Acting Secretary Julie Su in Uniontown to ...
The company said that the approval was based on results from the Phase 3 Papillon study, which demonstrated that Rybrevant plus chemotherapy reduced the risk of disease progression or death by 60 ...
AI’s ability to outperform human lung cancer detection is rapidly evolving, as was highlighted in the clinical science ...
The following is a summary of “Circulating tumor DNA to guide diagnosis and treatment of localized and locally advanced ...
First of Multiple Planned Global Submissions for Lifileucel in 2024 and 2025Key Step in Global Expansion to Address >20,000 Patients Annually ...
If patients have smoked and have no symptoms of lung cancer, a screening could save their lives. Individuals who may be eligible or have loved ones who meet current guidelines to receive a low-dose CT ...
The Filipino branch of the Swedish pharmaceutical company AstraZeneca, AC Health, Cancer Coalition Philippines, and the ...
Oncology specialists from around the world came together for the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting to discuss the latest developments in cancer care, research, ...
The most advanced clinical stage product that BDTX is currently working ... heart of treatment for malignancies like colon ...
Results from a new study led by researchers at The University of Texas MD Anderson Cancer Center support standard use of the ...
lung and gastric cancers, in partnership with AstraZeneca (NASDAQ:AZN). Daiichi Sankyo and AstraZeneca have also developed datopotamab deruxtecan (Dato-DXd), a TROP2-directed ADC. Dato-DXd is under ...